Maternal weight correction of maternal serum PAPP-A and free β-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy

Prenatal Diagnosis

Volumn 23, Issue 10, 2003, Pages 851-855

  Spencer, Kevin ^a   Bindra, Renu ^b   Nicolaides, Kypros H ^b  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Down syndrome; Prenatal screening

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; BODY WEIGHT; DOWN SYNDROME; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; TRISOMY 21; ULTRASOUND;

ADULT; BIOLOGICAL MARKERS; BODY WEIGHT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES;

EID: 0142137213     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.708     Document Type: Article

References (13)

1. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. 2002. One stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynaecol 20: 219-225.
2. Kennedy DM, Edwards VM, Worthington DJ. 1999. Evaluation of different weight correction methods for antenatal serum screening using data from two multi-centre programmes. Ann Clin Biochem 36: 359-364.
3. Neveux LM, Palomaki GE, Larivee DA, Knight GJ, Haddow JE. 1996. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 16: 7123-7723.
4. Reynolds TM, Penney MD, Hughes H, John R. 1991. The effect of weight correction on risk calculations for Down's syndrome screening. Ann Clin Biochem 28: 245-249.
5. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. A multicentre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 18: 519-521.
6. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
7. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. 2000a. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 107: 1271-1275.
8. Spencer K, Ong CYT, Liao AWJ, Nicolaides KH. 2000b. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn 20: 491-494.
9. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. 2003. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. Br J Obstet Gynaecol 110: 281-286.
10. Wald NJ, Cuckle H, Boreham J, Terzian E, Redman C. 1981. The effect of maternal weight on maternal serum alpha-fetoprotein levels. Br J Obstet Gynaecol 88: 1094-1096.
11. Wald NJ, Cuckle HS, Densem JW, Kennard A, Smith D. 1992. Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight. Br J Obstet Gynaecol 99: 144-149.
12. Wald NJ, Densem JW, Smith D, Klee GG. 1994. Four marker screening for Down's syndrome. Prenat Diagn 14: 706-716.
13. Watt HC, Wald NJ. 1998. Alternative methods of maternal weight adjustment in maternal serum screening for Down syndrome and neural tube defects. Prenat Diagn 18: 842-845.